Patents by Inventor Sung Ji Kim

Sung Ji Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210268060
    Abstract: The present invention relates to a composition for use in preventing, alleviating, or treating inflammatory disease, or an anti-inflammatory composition, which comprises: ?-1,3-glucan; and the peptide composed of the amino acid sequence of SEQ ID NO: 4. The present invention also relates to an antibacterial composition against bacteria causative of sepsis, which comprises: ?-1,3-glucan; the peptide composed of the amino acid sequence of SEQ ID NO: 4; and an antibiotic. The present invention also relates to a method for preventing or treating an inflammatory disease, the method comprising a step of administering ?-1,3-glucan; and the peptide composed of the amino acid sequence of SEQ ID NO: 4 to a patient.
    Type: Application
    Filed: June 19, 2019
    Publication date: September 2, 2021
    Applicant: Quegen Biotech Co., Ltd.
    Inventors: Chul Su YANG, Young Kyun KIM, Byeong Hee PARK, Jong Dae LEE, Je Kyoung KIM, Yong Man JANG, Sung Hong KIM, Eun Ji PARK
  • Publication number: 20210260096
    Abstract: The present invention relates to a pharmaceutical composition for treating a wound or activating the skin, containing beta-glucan, glycitin (4?-hydroxy-6-methoxyisoflavone-7-D-glucoside), and 4?,6,7-trimethoxyisoflavone.
    Type: Application
    Filed: June 21, 2019
    Publication date: August 26, 2021
    Applicant: Quegen Biotech Co., Ltd.
    Inventors: Eun Ji PARK, Jong Dae LEE, Sung Hong KIM, Byeong Hee PARK, Young Kyun KIM
  • Patent number: 7097967
    Abstract: The present invention provides a method of predicting a food-drug interaction in vivo, in the case of an orally administered drug interactive with digestive enzymes in the gastrointestinal tract, by measuring the activity of the drug to the digestive enzymes in vitro, which is based on the fact that the ingestion of foods causes the absorption of drug in vivo to decrease due to the above interaction between a drug and digestive enzymes. The present invention further provides methods of minimizing the change of absorption in vivo caused by the ingestion of foods by reducing the action of digestive enzymes, for example, introduction of prodrugs, modification of the chemical structure of drug, design of drug formulation, etc.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: August 29, 2006
    Assignee: LG Life Sciences Ltd.
    Inventors: Aeri Kim, Kwan Hyung Cho, Sun Hwa Lee, Suk Kyoon Yoon, Hee Dong Park, Kyung Ha Chung, Ho Jun Kim, Han Joo Maeng, Tae Hun Kim, Bong Chan Kim, Sung Ji Kim
  • Publication number: 20050113309
    Abstract: The present invention relates to crystalline forms of (2S)-N-5-[amino(imino)methyl]-2-thienyl-methyl-1-(2R)-2-[(carboxymethyl)amino]-3,3-diphenylpropanoyl-2-pyrrolidinecarboxamide nH2O.
    Type: Application
    Filed: March 21, 2003
    Publication date: May 26, 2005
    Inventors: Aeri Kim, Jae-Hyeon Park, Suk-Kyoon Yoon, Bong-Chan Kim, Sung-Ji Kim, Kwan-Hyung Cho
  • Publication number: 20040229821
    Abstract: The present invention provides an orally administrable pharmaceutical composition for preventing the decrease in the bioavailability of a drug after food intake, comprising, i) said drug; and ii) a pharmaceutically acceptable bioadhesive polymer, particularly for effectively preventing the decrease in the drug absorption rate due to interaction with digestive enzymes or food ingredients after food intake.
    Type: Application
    Filed: February 23, 2004
    Publication date: November 18, 2004
    Inventors: Ae-Ri Kim, Kwan-Hyung Cho, Ji-Hye Lee, Sun-Hwa Lee, Ho-Jun Kim, Han-Joo Maeng, Hee-Dong Park, Tae-Hun Kim, Bong-Chan Kim, Sung-Ji Kim, Kyo-Seok Choo
  • Publication number: 20040081641
    Abstract: The present invention provides a method of predicting a food-drug interaction in vivo, in the case of an orally administered drug interactive with digestive enzymes in the gastrointestinal tract, by measuring the activity of the drug to the digestive enzymes in vitro, which is based on the fact that the ingestion of foods causes the absorption of drug in vivo to decrease due to the above interaction between a drug and digestive enzymes. The present invention further provides methods of minimizing the change of absorption in vivo caused by the ingestion of foods by reducing the action of digestive enzymes, for example, introduction of prodrugs, modification of the chemical structure of drug, design of drug formulation, etc.
    Type: Application
    Filed: October 24, 2002
    Publication date: April 29, 2004
    Applicant: LG LIFE SCIENCES LTD.
    Inventors: Aeri Kim, Kwan Hyung Cho, Sun Hwa Lee, Suk Kyoon Yoon, Hee Dong Park, Kyung Ha Chung, Ho Jun Kim, Han Joo Maeng, Tae Hun Kim, Bong Chan Kim, Sung Ji Kim